474 related articles for article (PubMed ID: 26407672)
21. Single-cell pharmacokinetic imaging reveals a therapeutic strategy to overcome drug resistance to the microtubule inhibitor eribulin.
Laughney AM; Kim E; Sprachman MM; Miller MA; Kohler RH; Yang KS; Orth JD; Mitchison TJ; Weissleder R
Sci Transl Med; 2014 Nov; 6(261):261ra152. PubMed ID: 25378644
[TBL] [Abstract][Full Text] [Related]
22. Nanoparticles-mediated drug delivery approaches for cancer targeting: a review.
Sultana S; Khan MR; Kumar M; Kumar S; Ali M
J Drug Target; 2013 Feb; 21(2):107-25. PubMed ID: 22873288
[TBL] [Abstract][Full Text] [Related]
23. Progress and challenges towards targeted delivery of cancer therapeutics.
Rosenblum D; Joshi N; Tao W; Karp JM; Peer D
Nat Commun; 2018 Apr; 9(1):1410. PubMed ID: 29650952
[TBL] [Abstract][Full Text] [Related]
24. Nanomedicine in veterinary oncology.
Lin TY; Rodriguez CO; Li Y
Vet J; 2015 Aug; 205(2):189-97. PubMed ID: 25862394
[TBL] [Abstract][Full Text] [Related]
25. A pharmacokinetic model for quantifying the effect of vascular permeability on the choice of drug carrier: a framework for personalized nanomedicine.
Kirtane AR; Siegel RA; Panyam J
J Pharm Sci; 2015 Mar; 104(3):1174-86. PubMed ID: 25583443
[TBL] [Abstract][Full Text] [Related]
26. Towards clinical translation of ligand-functionalized liposomes in targeted cancer therapy: Challenges and opportunities.
Belfiore L; Saunders DN; Ranson M; Thurecht KJ; Storm G; Vine KL
J Control Release; 2018 May; 277():1-13. PubMed ID: 29501721
[TBL] [Abstract][Full Text] [Related]
27. To exploit the tumor microenvironment: Passive and active tumor targeting of nanocarriers for anti-cancer drug delivery.
Danhier F; Feron O; Préat V
J Control Release; 2010 Dec; 148(2):135-46. PubMed ID: 20797419
[TBL] [Abstract][Full Text] [Related]
28. Pretargeting with bispecific anti-renal cell carcinoma x anti-DTPA(In) antibody in 3 RCC models.
van Schaijk FG; Oosterwijk E; Molkenboer-Kuenen JD; Soede AC; McBride BJ; Goldenberg DM; Oyen WJ; Corstens FH; Boerman OC
J Nucl Med; 2005 Mar; 46(3):495-501. PubMed ID: 15750164
[TBL] [Abstract][Full Text] [Related]
29. Tumor-Targeting Glycol Chitosan Nanoparticles for Cancer Heterogeneity.
Ryu JH; Yoon HY; Sun IC; Kwon IC; Kim K
Adv Mater; 2020 Dec; 32(51):e2002197. PubMed ID: 33051905
[TBL] [Abstract][Full Text] [Related]
30. Radioactive antibodies: a historical review of selective targeting and treatment of cancer.
Goldenberg DM; Sharkey RM
Hosp Pract (1995); 2010; 38(3):82-93. PubMed ID: 20890056
[TBL] [Abstract][Full Text] [Related]
31. Nanodrug delivery systems: a promising technology for detection, diagnosis, and treatment of cancer.
Babu A; Templeton AK; Munshi A; Ramesh R
AAPS PharmSciTech; 2014 Jun; 15(3):709-21. PubMed ID: 24550101
[TBL] [Abstract][Full Text] [Related]
32. Optimizing bispecific antibody pretargeting for use in radioimmunotherapy.
Sharkey RM; Karacay H; Richel H; McBride WJ; Rossi EA; Chang K; Yeldell D; Griffiths GL; Hansen HJ; Goldenberg DM
Clin Cancer Res; 2003 Sep; 9(10 Pt 2):3897S-913S. PubMed ID: 14506188
[TBL] [Abstract][Full Text] [Related]
33. Exploiting homing abilities of cell carriers: Targeted delivery of nanoparticles for cancer therapy.
Tiet P; Berlin JM
Biochem Pharmacol; 2017 Dec; 145():18-26. PubMed ID: 28941937
[TBL] [Abstract][Full Text] [Related]
34. Tumor heterogeneity and nanoparticle-mediated tumor targeting: the importance of delivery system personalization.
Swetha KL; Roy A
Drug Deliv Transl Res; 2018 Oct; 8(5):1508-1526. PubMed ID: 30128797
[TBL] [Abstract][Full Text] [Related]
35. Delta-like ligand 4-targeted nanomedicine for antiangiogenic cancer therapy.
Liu YR; Guan YY; Luan X; Lu Q; Wang C; Liu HJ; Gao YG; Yang SC; Dong X; Chen HZ; Fang C
Biomaterials; 2015 Feb; 42():161-71. PubMed ID: 25542804
[TBL] [Abstract][Full Text] [Related]
36. Therapeutic Applications of Pretargeting.
Verhoeven M; Seimbille Y; Dalm SU
Pharmaceutics; 2019 Sep; 11(9):. PubMed ID: 31480515
[TBL] [Abstract][Full Text] [Related]
37. Programmable nanomedicine: synergistic and sequential drug delivery systems.
Pacardo DB; Ligler FS; Gu Z
Nanoscale; 2015 Feb; 7(8):3381-91. PubMed ID: 25631684
[TBL] [Abstract][Full Text] [Related]
38. Biodegradable, polymeric nanoparticle delivery systems for cancer therapy.
Pridgen EM; Langer R; Farokhzad OC
Nanomedicine (Lond); 2007 Oct; 2(5):669-80. PubMed ID: 17976029
[TBL] [Abstract][Full Text] [Related]
39. Molecular advances in pretargeting radioimunotherapy with bispecific antibodies.
Chang CH; Sharkey RM; Rossi EA; Karacay H; McBride W; Hansen HJ; Chatal JF; Barbet J; Goldenberg DM
Mol Cancer Ther; 2002 May; 1(7):553-63. PubMed ID: 12479274
[TBL] [Abstract][Full Text] [Related]
40. Size matters: gold nanoparticles in targeted cancer drug delivery.
Dreaden EC; Austin LA; Mackey MA; El-Sayed MA
Ther Deliv; 2012 Apr; 3(4):457-78. PubMed ID: 22834077
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
